One year in review
Psoriatic arthritis: one year in review 2022
C. Cigolini1, F. Fattorini2, S. Gentileschi3, R. Terenzi4, L. Carli5
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
- Rheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Italy.
- USL Toscana Centro, Firenze, Italy.
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy. 81clinda@gmail.com
CER16095
2022 Vol.40, N°9
PI 1611, PF 1619
One year in review
Free to view
(click on article PDF icon to read the article)
PMID: 36129799 [PubMed]
Received: 29/07/2022
Accepted : 19/09/2022
In Press: 19/09/2022
Published: 19/09/2022
Abstract
Psoriatic arthritis is a systemic autoimmune disease, in which a characteristic heterogeneous inflammatory involvement of entheses and both peripheral and axial joints tends to be associated with different clinical features, in particular skin or nail psoriasis, but also inflammatory bowel diseases, or acute anterior uveitis. Patients with PsA are at higher risk of developing comorbidities, in particular metabolic syndrome, with a significant impact on their quality of life. Although the advanced knowledge in the pathogenetic mechanisms of PsA helped in developing an abundant therapeutical armamentarium, the available drugs might still show a suboptimal efficacy. However, the frontier of “personalised medicine” could promote further future improvement in the quality of care of patients. In this paper we reviewed the literature on PsA of 2020 and 2021 (Medline search of articles published from 1st January 2020 to 31th December 2021).
